Premium
Arbutus Biopharma Corporation (ABUS)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025...
Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -2.75229357798 | 3.27 | 3.37 | 3.16 | 630430 | 3.23032158 | CS |
| 4 | 0.03 | 0.952380952381 | 3.15 | 3.54 | 3.115 | 806862 | 3.28040829 | CS |
| 12 | -0.85 | -21.0918114144 | 4.03 | 4.03 | 3.11 | 852345 | 3.48139367 | CS |
| 26 | -0.52 | -14.0540540541 | 3.7 | 4.725 | 3.11 | 972952 | 3.81138603 | CS |
| 52 | 0.79 | 33.0543933054 | 2.39 | 4.725 | 2.265 | 1078068 | 3.34429039 | CS |
| 156 | 0.62 | 24.21875 | 2.56 | 4.725 | 1.69 | 1020432 | 2.84549677 | CS |
| 260 | 0.08 | 2.58064516129 | 3.1 | 9 | 0.88 | 2141175 | 3.71864601 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
